Accent Microcell Ltd H1 FY26 – The Powder Kings of Pharma with 17% Margins and Zero Debt Swagger
1. At a Glance
Ladies and gentlemen, welcome to the cellulose circus! Accent Microcell Ltd (AMC), the manufacturer of the humble-but-mighty pharmaceutical excipient — the invisible powder that makes your pills stick together and your pharma stock portfolio rise — has turned its H1 FY26 into a masterclass in quiet execution. As of November 2025, AMC’s stock trades at ₹306 on the NSE SME board, with a market cap of ₹733 crore, a P/E of 21.2x, and a balance sheet so clean even the auditors might feel unemployed — Debt: ₹1.15 crore.
Revenue for the latest half-year stands at ₹278 crore (TTM), with PAT at ₹35 crore, and ROCE at 23.7%, ROE at 18.4%. Not bad for a company that literally sells “filler material.” What’s more impressive? An Operating Profit Margin of 17%, exports contributing ~58% of revenue, and expansion plans to lift capacity from 8,000 MTPA to 12,000 MTPA in Gujarat.
They may not make the drugs, but they make the drugs possible. And that’s the quiet money zone. Now, let’s peel back the powder layers and see what really holds this tablet together.
2. Introduction
Every once in a while, a boring-looking company sneaks up the charts, quietly compounding cash while the market is busy chasing AI unicorns and PSU memes. Accent Microcell Ltd is one such legend in the making. Born in 2001, AMC has evolved from a small Gujarat-based excipient manufacturer to a globally certified pharma supplier that exports to 36 countries — from the US and Germany to Bangladesh and Thailand.
You may not have heard of them, but if you’ve popped a tablet today, there’s a good chance one of their products — Microcrystalline Cellulose (MCC) — was inside it. They don’t make life-saving drugs; they make the life-saving drugs look presentable and swallowable.
The company’s performance since its December 2023 IPO has been remarkable. Listed on NSE SME at ₹78.40 crore fresh issue, the stock has already multiplied almost 4x from its listing base. In a market where smallcaps blow up faster than Diwali crackers, AMC has stayed steady — like a Paracetamol in a world of painkillers.
Add to that: zero pledging, rising institutional shareholding (3.29%), and a promoter group that owns 55.44% — it’s a family-run setup that actually delivers on promises. The question is — can this pharmaceutical sidekick sustain its superhero-level margins?
3. Business Model – WTF Do They Even Do?
Think of AMC as the “Atta Chakki” of the pharma world — except instead of flour, it grinds out Microcrystalline Cellulose (MCC) and Cross Carmellose Sodium, the essential ingredients that make tablets form, bind, and disintegrate at the right moment.
Their product portfolio is split under three brand umbrellas:
Accel / Vincel: MCC and its variants (Cellulose Powder, Spheres, Silicified MCC)
Acrocell: Cross Carmellose Sodium (a disintegrant)
Maccel: Magnesium Stearate (a lubricant)
In simpler words — when your pill stays intact in your hand but melts gracefully in your stomach, that’s AMC’s doing.
The company operates two plants in Pirana and Dahej (Gujarat), with a combined capacity of ~8,000 MTPA, and is setting up a third unit in Navagam Kheda to make Sodium Starch Glycolate and Carboxymethylcellulose. Post expansion, total installed capacity will jump to ~12,000 MTPA.
With certifications like EXCiPACT, US-DMF, GMP, ISO 9001, and HACCP, AMC is punching well above the SME league. Serving 200+ customers across pharma, food, nutraceuticals, and cosmetics sectors, they’ve truly diversified their excipient empire.
The catch? Top 10 customers account for ~43% of revenue — up from 32% last year. Concentration risk is real, but when your clients include Brenntag, Dexcel Pharma, and Lehmann & Voss, you’re at least in good company.
4. Financials Overview
Source table
Metric
Latest Half (Sep FY26)
YoY Half (Sep FY25)
Prev Half (Mar FY25)
YoY %
QoQ %
Revenue
₹139 Cr
₹126 Cr
₹139 Cr
10.6%
0%
EBITDA
₹24 Cr
₹19 Cr
₹23 Cr
26%
4%
PAT
₹18.1 Cr
₹16.5 Cr
₹17 Cr
9.7%
6.5%
EPS (₹)
7.53
6.86
6.92
9.8%
8.8%
The earnings may not scream “multi-bagger,” but they whisper “consistent compounding.” At this rate, the annualised EPS = ₹7.53 × 2 = ₹15.06, giving a P/E of ~20.3x, slightly below its sector median (31x).
EBITDA margin steady at 17% — that’s better than some finished-drug companies! While most pharma giants are whining
